Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new technique allowing drugs or vaccines to be encapsulated within tiny biodegradable particles could see an end booster jabs

Multiple injections for vaccinations could become a thing of the past, according to scientists who have developed an approach for delivering many doses of different substances in just one jab.

The technology involves encapsulating drugs or vaccines within tiny particles made of biodegradable polymers. Depending on their makeup, these polymers break down at different points in time, releasing their contents into the body.

Researchers say the approach could allow multiple vaccines to be delivered at once and remove the need for booster jabs. It may also prove handy in treatments for allergies, diabetes and even cancer where multiple injections are needed.

Researchers say it could prove valuable in developing countries, potentially allowing all childhood vaccines and their boosters to be given in one shot.

“One of the main limitations there is access to vaccines and the fact that you have to come back several times in order to get immunity from the pathogen,” said Ana Jaklenec, co-author of the research from the Massachusetts Institute of Technology. “A child or a baby is usually seen once, sometime around the birth time by some sort of healthcare worker.”

Writing in the journal Science, Jaklenec and colleagues describe how they developed the novel technique using biodegradable polymers already approved for use in humans.

The process, they reveal, involves making tiny silicone moulds – rather like ice cube trays – into which the biodegradable polymers are pressed and removed to form an array of box-like structures, each about 400 micrometres across. These are then filled with the required drug or vaccine and allowed to dry.

A lid, made from the same polymer, is then lined up on top of each micro-box and the system is briefly heated to seal it and prevent the drug or vaccine from leaking out.

When injected into the body, the boxes remain sealed until the polymer disintegrates – an event which occurs rapidly, with the timing dependant on the makeup of the polymer itself.

This post originally appears on www.theguardian.com: https://www.theguardian.com/society/2017/sep/14/multiple-time-delayed-drugs-could-be-given-in-single-injection-say-scientists

Similar stories

New survey launched to explore the acceptability of the Gonococcal Controlled Human Infection Model in UK men.

Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.

Oxford Ebola vaccine manufactured and shipped in record time by SII

More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.

From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford

Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.